Spots Global Cancer Trial Database for papillary renal cell carcinoma
Every month we try and update this database with for papillary renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | NCT02489695 | Papillary Renal... | Axitinib | 18 Years - | Centre Leon Berard | |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | NCT06339138 | Chromophobe Ren... Clear Cell Papi... Clear Cell Rena... Kidney Oncocyto... Papillary Renal... Urothelial Carc... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | NCT05665361 | Advanced Clear ... Papillary Renal... | Sasanlimab Palbocicilib | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | NCT00126503 | Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | NCT02489695 | Papillary Renal... | Axitinib | 18 Years - | Centre Leon Berard | |
| Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery | NCT01164228 | Kidney Cancer | Gemcitabine Sunitinib | 18 Years - | Eastern Cooperative Oncology Group | |
| DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE | NCT00900536 | Kidney Cancer | mutation analys... polymorphism an... protein express... immunohistochem... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy | NCT06146777 | Papillary Renal... | Pembrolizumab Placebo | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | NCT03635892 | Advanced or Met... Unclassified Re... Papillary Renal... Fumarate Hydrat... Succinate Dehyd... Collecting Duct... Chromophobe Ren... | cabozantinib nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | NCT04413123 | Papillary Renal... Unclassified Re... Translocation R... Chromophobe Ren... Collecting Duct... Renal Cell Carc... Unresectable Ad... Metastatic Ncc ... | Cabozantinib Nivolumab Ipilimumab | 18 Years - | Dana-Farber Cancer Institute | |
| Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05620134 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Melanoma Colorectal Canc... Non-small Cell ... Small-cell Lung... Urothelial Carc... Squamous Cell C... Luminal Breast ... Triple Negative... Clear Cell Rena... Papillary Renal... Gastric Adenoca... GastroEsophagea... Squamous Cell C... Pancreatic Aden... Hepatocellular ... Colorectal Aden... Epithelial Ovar... Thyroid Cancer | JK08 Pembrolizumab | 18 Years - | Salubris Biotherapeutics Inc | |
| Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer | NCT00401128 | Kidney Cancer | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | The Cleveland Clinic | |
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | NCT04413123 | Papillary Renal... Unclassified Re... Translocation R... Chromophobe Ren... Collecting Duct... Renal Cell Carc... Unresectable Ad... Metastatic Ncc ... | Cabozantinib Nivolumab Ipilimumab | 18 Years - | Dana-Farber Cancer Institute | |
| DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE | NCT00900536 | Kidney Cancer | mutation analys... polymorphism an... protein express... immunohistochem... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | NCT01767636 | Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Pazopanib Hydro... | 18 Years - | Mayo Clinic | |
| Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | NCT04603365 | Clear Cell Papi... Collecting Duct... Hereditary Leio... Hereditary Papi... Metastatic Rena... Metastatic Uncl... Papillary Renal... Stage III Renal... Stage IV Renal ... Tubulocystic Re... Unresectable Re... | Pamiparib Temozolomide | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | NCT06339138 | Chromophobe Ren... Clear Cell Papi... Clear Cell Rena... Kidney Oncocyto... Papillary Renal... Urothelial Carc... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | NCT01120249 | Kidney Cancer | everolimus placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | NCT03635892 | Advanced or Met... Unclassified Re... Papillary Renal... Fumarate Hydrat... Succinate Dehyd... Collecting Duct... Chromophobe Ren... | cabozantinib nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | NCT06339138 | Chromophobe Ren... Clear Cell Papi... Clear Cell Rena... Kidney Oncocyto... Papillary Renal... Urothelial Carc... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | NCT00126503 | Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery | NCT00459979 | Kidney Cancer | sunitinib malat... conventional su... | 18 Years - | Case Comprehensive Cancer Center | |
| Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery | NCT01164228 | Kidney Cancer | Gemcitabine Sunitinib | 18 Years - | Eastern Cooperative Oncology Group | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | NCT01767636 | Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Pazopanib Hydro... | 18 Years - | Mayo Clinic | |
| Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer | NCT00027573 | Kidney Cancer | filgrastim therapeutic all... cyclophosphamid... fludarabine pho... methotrexate tacrolimus peripheral bloo... | - 60 Years | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | NCT00335556 | Childhood Renal... Clear Cell Rena... Clear Cell Sarc... Papillary Renal... Rhabdoid Tumor ... Stage I Renal C... Stage I Renal W... Stage II Renal ... Stage II Renal ... Stage III Renal... Stage III Renal... Stage IV Renal ... Stage IV Renal ... | Doxorubicin Hyd... Irinotecan Hydr... Conventional Su... Cyclophosphamid... Etoposide Carboplatin Dactinomycin Vincristine Sul... Radiation Thera... Laboratory Biom... | - 29 Years | Children's Oncology Group | |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | NCT05665361 | Advanced Clear ... Papillary Renal... | Sasanlimab Palbocicilib | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | NCT01120249 | Kidney Cancer | everolimus placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | NCT00601926 | Kidney Cancer | bevacizumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer | NCT00401128 | Kidney Cancer | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | The Cleveland Clinic | |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | NCT04623502 | Kidney Cancer Renal Cell Carc... Clear Cell Carc... Urothelial Carc... Metastatic Kidn... Metastatic Urot... Papillary Renal... Chromophobe Ren... Fumarate Hydrat... Succinate Dehyd... HLRCC Hereditary Leio... | 13C-Glucose 13C-Acetate 13C-Lactate 13C-Glutamine 13C-Fructose | 18 Years - | University of Texas Southwestern Medical Center | |
| Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer | NCT00492258 | Kidney Cancer | sorafenib tosyl... adjuvant therap... | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | NCT03866382 | Bladder Adenoca... Bladder Clear C... Bladder Mixed A... Bladder Neuroen... Bladder Small C... Bladder Squamou... Chromophobe Ren... Collecting Duct... Invasive Bladde... Invasive Bladde... Invasive Bladde... Invasive Bladde... Invasive Bladde... Invasive Bladde... Kidney Medullar... Large Cell Neur... Malignant Testi... Malignant Testi... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Blad... Metastatic Chro... Metastatic Kidn... Metastatic Mali... Metastatic Papi... Metastatic Peni... Metastatic Pros... Metastatic Sarc... Metastatic Uret... Papillary Renal... Sarcomatoid Ren... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Urethr... Stage IVB Prost... Urachal Adenoca... Urethral Clear ... | Bone Scan Cabozantinib S-... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | NCT04981509 | Hereditary Leio... Papillary Renal... Renal Cell Carc... Sporadic Papill... Stage III Renal... Stage IV Renal ... | Atezolizumab Bevacizumab Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Computed Tomogr... Erlotinib Magnetic Resona... Positron Emissi... Sodium Fluoride... | 12 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study | NCT04071223 | Advanced Renal ... Chromophobe Ren... Clear Cell Rena... Collecting Duct... Kidney Medullar... Metastatic Mali... Papillary Renal... Stage IV Renal ... Unclassified Re... | Cabozantinib S-... Quality-of-Life... Questionnaire A... Radium Ra 223 D... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
